Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism

Last updated: August 3, 2026
Sponsor: Stephanie B. Seminara, MD
Overall Status: Completed

Phase

2

Condition

Hypogonadism

Hormone Deficiencies

Treatment

kisspeptin 112-121

GnRH

Clinical Study ID

NCT04648969
313509
  • Ages > 18
  • All Genders

Study Summary

The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.

Eligibility Criteria

Inclusion

Inclusion/exclusion criteria:

  • Age 18 years and older,

  • Confirmed diagnosis of HH with

  • Low testosterone or estradiol,

  • Low or low-normal gonadotropin levels,

  • Thyroid stimulating hormone (TSH) and prolactin within the reference range,

  • Absence of abnormal pituitary or hypothalamic findings on Magnetic resonance imaging (MRI),

  • All other medical conditions stable and well controlled,

  • No prescription medications known to affect reproductive endocrine function for at least 2 months or for 5 half-lives of the drug (whichever is shorter) except for medications used to treat the subject's reproductive condition,

  • No history of a medication reaction requiring emergency medical care,

  • No illicit drug use,

  • No excessive alcohol consumption (<10 drinks/week),

  • Normal blood pressure (BP), (systolic BP < 140 mm Hg, diastolic < 90 mm Hg),

  • White blood cell, platelet counts, and TSH between 90% of the lower limit and 110% of the upper limit of the reference range,

  • Prolactin below 110% of the upper limit of the reference range,

  • Hemoglobin

  • Women: no less than 0.5 gm/dL below the lower limit of the reference range for normal women,

  • Men: on adequate testosterone replacement therapy: normal male reference range,

  • Blood urea nitrogen (BUN), creatinine, aspartate aminotransferase (AST), alanine transaminase (ALT) not elevated,

  • For women,

  • Negative serum human chorionic gonadotropin (hCG) pregnancy test at the time of screening (additional urine pregnancy test will be conducted prior to drug administration),

  • Not breastfeeding and not pregnant.

Study Design

Total Participants: 18
Treatment Group(s): 2
Primary Treatment: kisspeptin 112-121
Phase: 2
Study Start date:
May 03, 2019
Estimated Completion Date:
August 31, 2025

Study Description

  • Assignment: Each study subject will serve as their own control. The order of kisspeptin doses will be randomized within each set/exposure.

  • Delivery of Interventions:

    • Prior to the study visit, subjects will undergo a review of their medical history and screening laboratories. Subjects will also wear a gonadotropin releasing hormone (GnRH) pump prior to the inpatient study visit.

    • On the day of the inpatient study, the subjects will

      • Undergo q10 min blood sampling for 6 hours,

      • Receive kisspeptin intravenous (IV) boluses from hour 6 to hour 44 (20 boluses total),

      • Undergo q10 min blood samplings for another 6 hours,

      • Receive a single GnRH IV bolus at hour 51.

Connect with a study center

  • Massachusetts General Hospital

    Boston, Massachusetts 02114
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.